Mounjaro quotes from clinical trials and official guidance: what they really mean

Where the most-quoted Mounjaro figures actually come from

When you see a quote like "lost 20% of their body weight", it almost always traces back to SURMOUNT-1, a 72-week randomised controlled trial involving 2,539 adults with obesity who did not have type 2 diabetes. Participants received tirzepatide at one of three doses (5mg, 10mg or 15mg) or a placebo, alongside a reduced-calorie diet and increased physical activity. At the highest dose, average weight reduction was around 20–21% of starting body weight. Some analyses of completers (people who finished all 72 weeks) produced figures approaching 22–23%, which is where the upper end of quoted ranges comes from.

Two things are easy to miss when those numbers circulate online. First, they are averages: some participants lost more, others less. Second, the lifestyle component was real and structured. The trial was not testing the drug in isolation. The NHS medicines page for tirzepatide frames it clearly: Mounjaro works alongside a reduced-calorie diet and increased activity, not instead of them. That framing matters when you weigh up what any quoted figure is actually promising.

Treatment starts at a 2.5mg weekly dose (a step designed to let your body adjust) and is titrated upward by your prescriber over several months. The impressive figures are associated with the higher maintenance doses reached after that titration process is complete, and if you want practical guidance on where on the body you can use Mounjaro injection sites, that detail is worth reading before you begin.

The head-to-head result that changed the comparison conversation

For a long time, comparisons between tirzepatide and semaglutide relied on indirect analyses across separate trials. That changed with SURMOUNT-5, a direct head-to-head study published in the New England Journal of Medicine in 2025. It enrolled 751 adults with obesity and no diabetes and ran for 72 weeks, comparing tirzepatide at its full dose range against semaglutide 2.4mg (the standard Wegovy maintenance dose). Tirzepatide produced greater average weight reduction across the board.

If you want to understand why, the mechanism is relevant. Mounjaro activates two gut-hormone pathways (GIP and GLP-1 receptors) while semaglutide targets GLP-1 alone. That dual action is thought to account for the difference in average outcomes. It also makes Mounjaro the only dual-agonist weight-loss medicine currently licensed in the UK.

The SURMOUNT-5 result is now part of how NICE's appraisal of tirzepatide (TA1026) frames indirect comparisons between the two treatments. The committee noted that evidence favours tirzepatide over semaglutide 2.4mg for average weight reduction, though which medicine is right for a specific person remains a clinical question, not a statistical one.

What the quotes miss: side effects, stopping rules and the five-percent check

You rarely see the side-effect data quoted alongside the weight-loss figures, but it belongs in the same conversation. The most common effects in SURMOUNT-1 were gastrointestinal: nausea, diarrhoea, vomiting and constipation. These were typically most noticeable around a dose increase and tended to settle after a couple of weeks. Most people in the trial tolerated the medicine well enough to continue, but a meaningful minority did stop due to side effects, that detail belongs in any honest reading of the results.

NICE's guidance also includes a stopping rule that rarely makes it into quoted headlines. If fewer than five percent of starting body weight is lost after six months at the highest tolerated dose, continuing treatment is reviewed. That threshold exists because the medicine does not produce the same response in everyone. Understanding the full cost picture is partly about understanding that outcome is not guaranteed.

One thing people often tell us they wish they had grasped earlier is that the 20% figure belongs to a population average at a specific dose after 72 weeks, not a minimum anyone can bank on from their first pen. That is not a reason to be pessimistic; the evidence base is genuinely strong. It is a reason to go in with an honest picture rather than a marketing headline, so it also helps to know which Mounjaro jab sites are recommended and how to rotate them correctly before you start.

How NICE and the NHS use these figures for eligibility decisions

The trial data fed directly into NICE's recommendation. TA1026 recommends tirzepatide for adults with a BMI of 35 or above plus at least one weight-related condition (such as high blood pressure, type 2 diabetes or obstructive sleep apnoea) within an NHS specialist weight management pathway. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. The phased NHS rollout means that even people who meet the criteria may be waiting for access through their GP surgery or a specialist service.

Private prescribing follows the licensed criteria rather than NICE's NHS-specific thresholds. Adults with a BMI of 30 or above (or 27 or above with a relevant weight-related condition) may be eligible, subject to a full clinical assessment. A fuller overview of Mounjaro's UK licence and how it works covers those eligibility details in more depth. The prescriber's job is to map the published evidence onto your specific situation; the quoted figures give them a starting point, not a script.

If you are weighing up whether treatment might suit you, checking your eligibility through a free consultation is the practical next step. A GPhC-registered prescriber reads every submission (a real clinician, not an automated system) and gives you an honest answer based on your health picture rather than a population average.